AU2012230809B2 - Methods and compositions for improving antiangiogenic therapy with anti-integrins - Google Patents

Methods and compositions for improving antiangiogenic therapy with anti-integrins Download PDF

Info

Publication number
AU2012230809B2
AU2012230809B2 AU2012230809A AU2012230809A AU2012230809B2 AU 2012230809 B2 AU2012230809 B2 AU 2012230809B2 AU 2012230809 A AU2012230809 A AU 2012230809A AU 2012230809 A AU2012230809 A AU 2012230809A AU 2012230809 B2 AU2012230809 B2 AU 2012230809B2
Authority
AU
Australia
Prior art keywords
antibody
integrin
beta
vegf
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012230809A
Other languages
English (en)
Other versions
AU2012230809A1 (en
Inventor
Manish Kumar Aghi
Warren Shawn Carbonell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2012230809A1 publication Critical patent/AU2012230809A1/en
Application granted granted Critical
Publication of AU2012230809B2 publication Critical patent/AU2012230809B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012230809A 2011-03-23 2012-03-22 Methods and compositions for improving antiangiogenic therapy with anti-integrins Active AU2012230809B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466791P 2011-03-23 2011-03-23
US61/466,791 2011-03-23
PCT/US2012/030204 WO2012129448A1 (en) 2011-03-23 2012-03-22 Methods and compositions for improving antiangiogenic therapy with anti-integrins

Publications (2)

Publication Number Publication Date
AU2012230809A1 AU2012230809A1 (en) 2013-10-10
AU2012230809B2 true AU2012230809B2 (en) 2017-06-29

Family

ID=46879749

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012230809A Active AU2012230809B2 (en) 2011-03-23 2012-03-22 Methods and compositions for improving antiangiogenic therapy with anti-integrins

Country Status (9)

Country Link
US (3) US20140079637A1 (enExample)
EP (1) EP2688585B1 (enExample)
JP (1) JP2014523398A (enExample)
KR (1) KR20140030153A (enExample)
CN (1) CN103561761A (enExample)
AU (1) AU2012230809B2 (enExample)
CA (1) CA2830908C (enExample)
ES (1) ES2699532T3 (enExample)
WO (1) WO2012129448A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830908C (en) * 2011-03-23 2019-09-24 Warren Shawn Carbonell Methods and compositions for improving antiangiogenic therapy with anti-integrins
WO2014105910A1 (en) 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
EP3067369A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the treatment of anti-angiogenic resistant cancer
EP3067698A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf as biomarker of cancer
US11578110B2 (en) 2015-08-25 2023-02-14 Histide Ag Compounds for inducing tissue formation and uses thereof
DK3349778T3 (da) * 2015-09-17 2021-11-22 Histide Ag Farmaceutisk association af vækstfaktorreceptoragonist og adhæsionsproteininhibitor til omdannelse af en neoplastisk celle til en ikke-neoplastisk celle og anvendelser deraf
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
AU2016323407A1 (en) * 2015-09-17 2018-04-19 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2020145669A1 (ko) * 2019-01-10 2020-07-16 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117976A2 (en) * 2004-06-03 2005-12-15 The Regent Of The University Of California Method of increasing radiation sensitivity by inhibition of beta one integrin
WO2009009114A2 (en) * 2007-07-12 2009-01-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20090220504A1 (en) * 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
US5840300A (en) 1995-09-11 1998-11-24 Trustees Of The University Of Pennsylvania Methods and compositions comprising single chain recombinant antibodies
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
US6596276B1 (en) 1997-09-30 2003-07-22 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6716410B1 (en) 1999-10-26 2004-04-06 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
JP3789066B2 (ja) 1999-12-08 2006-06-21 三菱電機株式会社 液晶表示装置
US8725620B2 (en) 2000-07-10 2014-05-13 Nobuyoshi Morimoto System and method for negotiating improved terms for products and services being purchased through the internet
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1414491A4 (en) 2001-07-09 2005-07-06 Elan Pharm Inc METHOD OF INHIBITING THE TOXICITY OF AMYLOID
WO2003047523A2 (en) 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
GEP20084439B (en) 2004-01-23 2008-07-25 Amgen Inc Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP4997432B2 (ja) * 2006-02-10 2012-08-08 学校法人慶應義塾 神経幹細胞の増殖抑制剤
ZA200807754B (en) * 2006-03-21 2009-12-30 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
WO2008031064A1 (en) * 2006-09-07 2008-03-13 University Of South Florida Hyd1 peptides as anti-cancer agents
WO2009018226A2 (en) * 2007-07-27 2009-02-05 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
EP2060287B1 (de) * 2007-11-14 2011-06-15 BrainLAB AG Medikamentenzuführungssystem für CED (Convection Enhanced Delivery)-Katheterinfusionen
CA2734863A1 (en) * 2008-08-20 2010-02-25 New York Blood Center, Inc. Regulation of integrin surface expression
CA2748161A1 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
NZ594343A (en) * 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
CA2830908C (en) * 2011-03-23 2019-09-24 Warren Shawn Carbonell Methods and compositions for improving antiangiogenic therapy with anti-integrins
WO2014105910A1 (en) * 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117976A2 (en) * 2004-06-03 2005-12-15 The Regent Of The University Of California Method of increasing radiation sensitivity by inhibition of beta one integrin
US20090220504A1 (en) * 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
WO2009009114A2 (en) * 2007-07-12 2009-01-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
CA2830908C (en) 2019-09-24
CA2830908A1 (en) 2012-09-27
WO2012129448A1 (en) 2012-09-27
EP2688585A4 (en) 2015-05-06
US20220111045A1 (en) 2022-04-14
AU2012230809A1 (en) 2013-10-10
US20140079637A1 (en) 2014-03-20
CN103561761A (zh) 2014-02-05
JP2014523398A (ja) 2014-09-11
KR20140030153A (ko) 2014-03-11
EP2688585A1 (en) 2014-01-29
ES2699532T3 (es) 2019-02-11
EP2688585B1 (en) 2018-09-05
US20180236073A1 (en) 2018-08-23
US11185585B2 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
US20220111045A1 (en) Methods and Compositions for Improving Antiangiogenic Therapy with Anti-Integrins
US12583927B2 (en) Anti-variable MUC1* antibodies and uses thereof
CN102596998B (zh) 血管增殖病症的治疗
KR102608028B1 (ko) 인간 원형질막 소포 관련 단백질 pv-1에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
US10106601B2 (en) Inhibition of PLGF to treat philadelphia chromosome positive leukemia
TWI669312B (zh) 抑制scube2，一新穎vegfr2輔受體，遏止腫瘤血管新生
US20090017011A1 (en) Modulation of vegf-c/vegfr-3 interactions in the treatment of rheumatoid arthritis
US11078272B2 (en) Treatment of pediatric brain tumors with targeting of CD47 pathway
TW201712033A (zh) 用於對抗血管新生及腫瘤標靶治療之對抗第二型血管內皮生長受體之人類抗體
WO2023172989A2 (en) Epo receptor agonists and antagonists
KR20240040068A (ko) 메조텔린을 특이적으로 표적화하는 조작된 면역 세포 및 이의 용도
EP3440111B1 (en) Anti-vegfr-1 antibodies and uses thereof
CN113368232B (zh) 多特异性抗原结合蛋白及其应用
KR102207221B1 (ko) 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법
KR20260028006A (ko) 억제성 항-cd93 항체
WO2023105528A1 (en) Antibodies specific to ceacam1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)